PWSA Blog

A Message from Soleno Therapeutics: Reflecting on One Year of VYKAT XR

One year ago, on March 26, 2025, the Prader-Willi syndrome community reached a historic milestone. For the first time, a treatment, VYKAT™ XR (diazoxide choline), was approved by the FDA specifically for hyperphagia in individuals ages 4 and older living with PWS. For a community that has long understood hyperphagia as the most urgent and defining challenge for our loved ones, this approval marked a significant moment in the history of PWS care and research.

Hyperphagia, which is the chronic, intense, and persistent feeling of hunger, shapes nearly every aspect of daily life for individuals with PWS and their families. The approval of a treatment targeting this hallmark symptom was the result of decades of advocacy, research, and perseverance by the PWS community.

To mark the one-year anniversary of this milestone, Soleno Therapeutics has shared a letter with the PWS community reflecting on the past year.

Read Soleno’s full letter at the button below.

Learn More About VYKAT XR

For those seeking more information about VYKAT XR, the following resources may be a helpful starting point. As always, we encourage families to speak with their healthcare provider to determine the best course of care for their loved one.

Soleno Therapeutics’ official VYKAT XR patient information page

VYKAT XR FAQ for Parents

VYKAT XR Medication Guide

VYKAT XR Prescribing Information

VYKAT XR Resources

Share this!

Scroll to top